Skip to content
ATLAS PREP HQ
Healing

KPV

Lys-Pro-Val, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone

Anti-inflammatory tripeptide research derived from alpha-MSH and studied in inflammatory signaling models.

Preclinical Evidence

Route

Subcutaneous in the community protocol

Common format

10 mg vial

Research focus

inflammatory bowel disease models

Evidence level

Preclinical Evidence

Typical cycle

8–12 weeks

Healing research motifHealing

KPV in 30 seconds

Atlas Fast Read

What it is

Lys-Pro-Val, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone

Why people care

Anti-inflammatory tripeptide research derived from alpha-MSH and studied in inflammatory signaling models.

Human evidence

Preclinical Evidence — The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

Biggest misconception

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Bottom line

KPV is scientifically interesting for inflammatory bowel disease models, skin inflammation, but the current case is driven mainly by cell and animal data.

Overview

What is KPV?

KPV is lys-Pro-Val, the C-terminal tripeptide of alpha-melanocyte-stimulating hormone. Anti-inflammatory tripeptide research derived from alpha-MSH and studied in inflammatory signaling models.

KPV is the three-amino-acid C-terminal fragment of alpha-MSH. Research separated its anti-inflammatory activity from the pigmentary effects of full melanocortin peptides.

Mechanism

How it works

Retains anti-inflammatory actions of alpha-MSH without melanotropic signaling. Preclinical models suggest suppression of NF-kB and pro-inflammatory cytokines and effects on intestinal/skin inflammatory pathways.

Research areas

inflammatory bowel disease modelsskin inflammationsystemic inflammationimmune signaling

Evidence

What does the evidence actually say?

Preclinical Evidence

The exact compound or use is supported mainly by animal, in-vitro, or mechanistic work, or lacks meaningful controlled human efficacy evidence.

01

Preclinical Evidence

02

Limited Human Evidence

03

Strong Human Evidence

Human evidence

No robust controlled human therapeutic trials establish KPV for inflammatory bowel disease, skin inflammation, or systemic inflammatory conditions. The evidence base remains predominantly preclinical.

Preclinical evidence

Cell and animal models show suppression of NF-kB and inflammatory cytokines, with signals in colitis, skin inflammation, and immune regulation. Human translation remains minimal.

Knowledge gaps

Key gaps include validated human dosing, pharmacokinetics, long-term safety, clinically meaningful efficacy, product standardization, and independent replication in well-controlled trials.

Protocol

Research protocol

DoseFrequencyTimingCycle

Dose

Community research reference: 200–500 mcg/day with weekly titration.

Frequency

Once daily.

Timing

No established time-of-day requirement.

Route

Subcutaneous in the community protocol; oral/topical delivery is also discussed experimentally but lacks standardized human dosing.

Cycle length

8–12 weeks

Reconstitution

Community reference: 1 mL bacteriostatic water per 10 mg vial = 10 mg/mL.

Storage

Community reference: lyophilized frozen; reconstituted 2–8 °C; avoid repeated freeze-thaw.

Monitoring

No validated monitoring standard. For inflammatory research, symptoms plus CRP and condition-specific markers may be useful; CBC/CMP are general safety context.

Protocols vary widely between sources. Investigational compounds are not approved therapies, and approved products should follow their official labeling. Nothing here is medical advice.

Safety

Safety, side effects, and precautions

Side effects

Controlled human safety data are limited. Possible issues include injection-site reactions, headache, nausea, dizziness, fatigue and hypersensitivity. Because several proposed mechanisms involve angiogenesis or tissue-growth signaling, long-term systemic effects are uncertain.

Contraindications

No validated human contraindication profile exists. Pregnancy/breastfeeding, active malignancy, unexplained masses, major bleeding disorders or serious systemic illness warrant avoidance outside formal research/medical oversight.

Interactions

Formal interaction studies are lacking. Use with anticoagulants/antiplatelet drugs, growth-factor therapies, immunomodulators or other experimental repair peptides creates unknown additive risks.

Stacks

Common stacks

KPV + BPC-157

Discussed for inflammatory gut/tissue research because mechanisms differ.

Preclinical/community rationale only; no controlled human combination trial.

Questions

FAQ

References

Sources

Atlas

The Atlas verdict

KPV is scientifically interesting for inflammatory bowel disease models, skin inflammation, but the current case is driven mainly by cell and animal data. Atlas would treat claimed benefits as hypotheses—not established human outcomes—and would put human safety, product quality, and controlled trials ahead of protocol optimization.

More in Healing

Healing

Ara-290

Innate-repair-receptor peptide research centered on inflammation, tissue protection, and neuropathy.

Read guide

Healing

BPC-157

Synthetic peptide studied primarily for tissue repair, cytoprotection, and gastrointestinal healing pathways.

Read guide

Healing

BPC-157 + TB-500

Combination research pairing BPC-157 and TB-500 for tissue repair, wound healing, and musculoskeletal recovery.

Read guide